The administration of BCP at a dose of 50 mg/kg prevents or reduces alterations in the intestinal barrier in the colon caused by obesity in the expression of Claudin-1, as well as a decrease in serum levels of endotoxemia and leptin, and an activity in bacterial dysbiosis, in which it acts as a selective regulator of the diet-dependent phyla, in addition to a possible stimulating effect on the differentiation of goblet cells. The gene discussed is CLDN1; the disease is Obesity.